Skip to main content

Table 2 Disease activity, HAQ score and laboratory parameters of inflammation during the study

From: Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study

 

M0 (N = 107)

M1 (N = 106)

M3 (N = 104)

M6 (N = 97)

M12 (N = 77)

P*, M0 vs M6 (N = 97)

P*, M0 vs M12 (N = 77)

P#

DAS28-ESR

4.93 ± 1.3

3.55 ± 1.2

2.8 ± 1.2

2.5 ± 1.2

2.3 ± 1.3

<  10−4

<  10−4

<  10−4

HAQ

1.4 ± 0.6

Not evaluated

Not evaluated

0.97 ± 0.6

0.98 ± 0.6

<  10−4

<  10−4

<  10−4

ESR (mm/h)

27.8 ± 22.8

8.2 ± 8.4

6.5 ± 10.2

6.1 ± 7.1

5.8 ± 1.8

<  10−4

<  10−4

<  10−4

CRP (mg/L)

17.7 ± 26.7

5.4 ± 15.4

4.7 ± 12.8

2.4 ± 4.4

2.3 ± 4.5

<  10−4

<  10−4

<  10−4

IL-6 (pg/mL)

26.4 ± 37.8

72.3 ± 76

62.3 ± 78.7

53.1 ± 58.7

53.8 ± 110

<  10−4

0.04

0.04

  1. Results are given as mean ± SD
  2. M month, HAQ health assessment questionnaire, ESR eythrocyte sedimentation rate, CRP C-reactive protein
  3. *Paired Student’s t test
  4. #Sensitivity analysis
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us